TY - JOUR
T1 - Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants
AU - Drakopoulos, Antonios
AU - Tzitzoglaki, Christina
AU - McGuire, Kelly
AU - Hoffmann, Anja
AU - Konstantinidi, Athina
AU - Kolokouris, Dimitrios
AU - Ma, Chunlong
AU - Freudenberger, Kathrin
AU - Hutterer, Johanna
AU - Gauglitz, Günter
AU - Wang, Jun
AU - Schmidtke, Michaela
AU - Busath, David D.
AU - Kolocouris, Antonios
N1 - Funding Information:
this research and the Ph.D. work of C.T.; J.W. thanks the support from NIH AI119187 and PhRMA Foundation 2015 Research Starter Grant in Pharmacology and Toxicology; A.H. and M.S. thank Andreas Sauerbrei for continuous kind support; A.K. and M.S. thank Professor Adolfo Garcia-Sastre group and the CEIRS program (NIAD Centers of Excellence for Influenza Research and Surveillance) for providing the Udorn virus.
Funding Information:
We are grateful to Chiesi Hellas for supporting this research and the Ph.D. work of C.T.; J.W. thanks the support from NIH AI119187 and PhRMA Foundation 2015 Research Starter Grant in Pharmacology and Toxicology; A.H. and M.S. thank Andreas Sauerbrei for continuous kind support; A.K. and M.S. thank Professor Adolfo Garcia-Sastre group and the CEIRS program (NIAD Centers of Excellence for Influenza Research and Surveillance) for providing the Udorn virus.
Publisher Copyright:
© 2018 American Chemical Society.
PY - 2018/3/8
Y1 - 2018/3/8
N2 - Recently, the binding kinetics of a ligand-target interaction, such as the residence time of a small molecule on its protein target, are seen as increasingly important for drug efficacy. Here, we investigate these concepts to explain binding and proton blockage of rimantadine variants bearing progressively larger alkyl groups to influenza A virus M2 wild type (WT) and M2 S31N protein proton channel. We showed that resistance of M2 S31N to rimantadine analogues compared to M2 WT resulted from their higher koff rates compared to the kon rates according to electrophysiology (EP) measurements. This is due to the fact that, in M2 S31N, the loss of the V27 pocket for the adamantyl cage resulted in low residence time inside the M2 pore. Both rimantadine enantiomers have similar channel blockage and binding kon and koff against M2 WT. To compare the potency between the rimantadine variants against M2, we applied approaches using different mimicry of M2, i.e., isothermal titration calorimetry and molecular dynamics simulation, EP, and antiviral assays. It was also shown that a small change in an amino acid at site 28 of M2 WT, which does not line the pore, seriously affects M2 WT blockage kinetics.
AB - Recently, the binding kinetics of a ligand-target interaction, such as the residence time of a small molecule on its protein target, are seen as increasingly important for drug efficacy. Here, we investigate these concepts to explain binding and proton blockage of rimantadine variants bearing progressively larger alkyl groups to influenza A virus M2 wild type (WT) and M2 S31N protein proton channel. We showed that resistance of M2 S31N to rimantadine analogues compared to M2 WT resulted from their higher koff rates compared to the kon rates according to electrophysiology (EP) measurements. This is due to the fact that, in M2 S31N, the loss of the V27 pocket for the adamantyl cage resulted in low residence time inside the M2 pore. Both rimantadine enantiomers have similar channel blockage and binding kon and koff against M2 WT. To compare the potency between the rimantadine variants against M2, we applied approaches using different mimicry of M2, i.e., isothermal titration calorimetry and molecular dynamics simulation, EP, and antiviral assays. It was also shown that a small change in an amino acid at site 28 of M2 WT, which does not line the pore, seriously affects M2 WT blockage kinetics.
KW - Influenza M2
KW - S31N mutation
KW - antiviral assay
KW - binding kinetics
KW - electrophysiology
KW - isothermal titration calorimetry
KW - molecular dynamic simulations
KW - rimantadine
KW - rimantadine enantiomers
KW - synthesis
UR - http://www.scopus.com/inward/record.url?scp=85043450434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043450434&partnerID=8YFLogxK
U2 - 10.1021/acsmedchemlett.7b00458
DO - 10.1021/acsmedchemlett.7b00458
M3 - Article
AN - SCOPUS:85043450434
SN - 1948-5875
VL - 9
SP - 198
EP - 203
JO - ACS Medicinal Chemistry Letters
JF - ACS Medicinal Chemistry Letters
IS - 3
ER -